BCAN

BYND Cannasoft Entering Production Agreements for its EZ-G Device

Retrieved on: 
Thursday, January 25, 2024
Hand, Oil, Sale, BYND, Pleasure, BCAN

ASHKELON, Israel and VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today that its EZ-G project team has arrived in Shenzhen, China to sign agreements with two of the largest manufacturers in the province to begin production of the EZ-G device and EZ-G Capsules.

Key Points: 
  • ASHKELON, Israel and VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today that its EZ-G project team has arrived in Shenzhen, China to sign agreements with two of the largest manufacturers in the province to begin production of the EZ-G device and EZ-G Capsules.
  • BYND Cannasoft intends to start mass production of its EZ-G device and EZ-G capsules after the Chinese New Year which ends on February 24, 2024.
  • Starting production of the EZ-G device and EZ-G capsules will allow BYND Cannasoft to meet its benchmark of starting the sale of the EZ-G device and EZ-G capsules in the second quarter of 2024, as announced in the Company’s previous press releases.
  • “This is a significant milestone for BYND Cannasoft as we are moving from the stage of developing the dream to realizing the dream in practice,” said Yftah Ben Yaackov, CEO and Director of BYND Cannasoft.

Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.

Retrieved on: 
Tuesday, January 16, 2024
Oncology, Health, Managed Care, General Health, Clinical Trials, Pharmaceutical, Biotechnology, RWE, Senior, Carcinoma in situ, Patient, Bladder cancer, Ferring Pharmaceuticals, CIS, BCG, Urinary bladder, BCAN, Investment, FDA, NMIBC, Bacillus, Pharmaceutical industry

Approved by the U.S. Food & Drug Administration (FDA) in December 2022, ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.

Key Points: 
  • Approved by the U.S. Food & Drug Administration (FDA) in December 2022, ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.
  • “With our significant manufacturing investments, we have achieved full product supply ahead of schedule.
  • Now that full product supply is available ahead of schedule, Ferring can end the temporary ADSTILADRIN Early Experience Program and dramatically increase patient access.
  • This ongoing study is exploring early utilization, experiences, and outcomes of ADSTILADRIN in the routine care setting.

Positive opinion from ISA-Israel patent office Provides the ability to file a patent application under the Patent Prosecution Highway (PPH) in the US

Retrieved on: 
Monday, December 18, 2023
Invention, Partner, PPH, PCT, Patent, BYND, BCAN, IP, European Patent Convention, EPO, 3D printing

A national phase application corresponding to inventive concept III of PCT/IL2022/050783 was filed on December 7, 2023, as a U.S. utility patent application under the Patent Prosecution Highway (PPH) and has been allocated the application number 18/567,766.

Key Points: 
  • A national phase application corresponding to inventive concept III of PCT/IL2022/050783 was filed on December 7, 2023, as a U.S. utility patent application under the Patent Prosecution Highway (PPH) and has been allocated the application number 18/567,766.
  • The Company also announced filing in 11 additional jurisdictions, including the European Patent Office (EPO), which includes 38 European countries.
  • The Company has strategically pursued accelerated processing through the Patent Prosecution Highway (PPH) for one of its inventions, aligning with international efforts to promote work-sharing among patent offices.
  • The Company is actively collaborating with legal experts, including Reinhold Cohn and Partners, to navigate the complex landscape of patent prosecution and ensure optimal outcomes.

Israel's Finance Ministry Increases Israel Innovation Authority's High-Tech Sector Fast-Track Fund to $100 Million During Wartime

Retrieved on: 
Thursday, November 16, 2023
Ministry, Research, CSE, Policy, Israel Innovation Authority, BCAN, GDP, Application, CRM, IIA, Non-economic damages caps, Ministry of Finance (Israel), Software, BYND, Growth, Finance minister, AI, Government, Renewable energy

Israel's Finance Ministry recently clarified its decision to increase the wartime high-tech sector fund to provide short- and long-term measures designed to assist startup companies in Israel’s high-tech sector.

Key Points: 
  • Israel's Finance Ministry recently clarified its decision to increase the wartime high-tech sector fund to provide short- and long-term measures designed to assist startup companies in Israel’s high-tech sector.
  • The Company was found suitable for submitting the application according to the criteria required in the grant program as detailed on the Israel Innovation Authority website.
  • Ministry officials recently met with prominent high-tech sector members, the Israel Innovation Authority (IIA), and other government representatives to discuss strategies for supporting companies during the ongoing conflict and formulate long-term industry plans for post-war recovery.
  • In 2022, it contributed over 18 percent of the national GDP, amounting to $78 billion (290 billion shekels), as the Israel Innovation Authority reported.

CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Tuesday, December 5, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, BCG, Woman, Food, NMIBC, BCAN, Carcinoma, Breakthrough therapy, Disease, Bladder cancer, Patient, Fast track (FDA), Caregiver, Cancer, SUO, Society, Bacillus, Pharmaceutical industry

CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.

Key Points: 
  • CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.
  • “Receiving both FDA Fast Track and Breakthrough Therapy Designation is an important milestone in the development of cretostimogene grenadenorepvec and for patients with bladder cancer who urgently need more therapeutic options,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology.
  • CG Oncology looks forward to working with the FDA to advance cretostimogene grenadenorepvec as a potential backbone therapy in bladder cancer.
  • “The Bladder Cancer Advocacy Network (BCAN) is grateful for the expedited review of this potential treatment option for bladder cancer patients with high-risk BCG-unresponsive NMIBC.

Israeli Ministry of Health Reports Surge in Medical Cannabis Patients Following Recent Events

Retrieved on: 
Tuesday, November 7, 2023
Cannabis, FDA, Spectrum, Intelligence, Psychiatry, Ageing, Ministry of Health (Israel), Family, Physician, Data collection, BYND, Pain Clinic, CSE, Ministry, BCAN, CRM, Epilepsy, Patient, Software as a service, Nursing, Pharmaceutical industry

Recent regulatory reforms approved by the Israeli Ministry of Healthi allows physicians to prescribe cannabis to patients as a first-line treatment rather than as an option of last resort.

Key Points: 
  • Recent regulatory reforms approved by the Israeli Ministry of Healthi allows physicians to prescribe cannabis to patients as a first-line treatment rather than as an option of last resort.
  • Israel has had a significant increase in the number of licensed medical cannabis patientsii in the wake of recent events, particularly the opening of the war in Gaza.
  • Physicians licensed to prescribe medical cannabis and Israeli Ministry of Health authorities have reported a notable surge in demand after the recent conflict.
  • Many of the medical cannabis patients receiving new licenses are war casualties, as doctors began issuing licenses for post-trauma to victims of the recent events.

Bladder Cancer Advocacy Network Announces Exclusive National Presenting Sponsorship by Ferring Pharmaceuticals for 2024 Walks to End Bladder Cancer

Retrieved on: 
Monday, October 2, 2023
Ferring Pharmaceuticals, Partnership, Bladder cancer, Research, Patient, City, Ferring, Health, Disease, Dietary supplement, Pharmaceutical industry, BCAN

BETHESDA, Md., Oct. 2, 2023 /PRNewswire/ -- Today, the Bladder Cancer Advocacy Network (BCAN) announced its exclusive partnership with Ferring Pharmaceuticals as the National Presenting Sponsor for its 2024 Walks to End Bladder Cancer. This landmark collaboration marks a significant milestone in the fight against bladder cancer and promises to raise awareness and funds to support bladder cancer research, patient education and support, and advocacy.

Key Points: 
  • BETHESDA, Md., Oct. 2, 2023 /PRNewswire/ -- Today, the Bladder Cancer Advocacy Network (BCAN) announced its exclusive partnership with Ferring Pharmaceuticals as the National Presenting Sponsor for its 2024 Walks to End Bladder Cancer.
  • "We are delighted and grateful to welcome Ferring Pharmaceuticals as our National Presenting Sponsor for the 2024 Walks to End Bladder Cancer," said Andrea Maddox-Smith, CEO of BCAN.
  • BCAN's Walks to End Bladder Cancer are signature awareness-building events hosted in multiple cities in the United States during May, Bladder Cancer Awareness Month.
  • The Walks include thousands of participants united in support of bladder cancer patients and families and help raise awareness of bladder cancer, the sixth-most diagnosed cancer in America.

BYND Cannasoft CEO Delivers Update Amidst Promising Milestones

Retrieved on: 
Thursday, August 3, 2023
Learning, Pressure, Male, CSE, Application virtualization, Investment, Marketing, Contract management, Woman, Research, BYND, Temperature, Publication, IP, PCT, Ministry, BCAN, Patent, Machine learning, Algorithm, Pleasure, Artificial intelligence, WIPO, AI, Health, Laboratory, Female, Medical device, 3D printing, Nursing

ASHKELON, Israel and VANCOUVER, British Columbia, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") today announced that Yftah Ben Yaackov, Chief Executive Officer and Director, shared a comprehensive update on the Company's progress, highlighting significant recent milestones and unveiling promising prospects for the future.

Key Points: 
  • ASHKELON, Israel and VANCOUVER, British Columbia, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") today announced that Yftah Ben Yaackov, Chief Executive Officer and Director, shared a comprehensive update on the Company's progress, highlighting significant recent milestones and unveiling promising prospects for the future.
  • BYND Cannasoft has been working diligently to establish a strong international presence.
  • BYND Cannasoft intends to capture a market share of about 3%, worth about $15 million in sales, within a year of putting its products on store shelves.
  • Yftah Ben Yaackov, CEO and Director of BYND said, "Our journey at BYND Cannasoft is shaping up to be nothing short of remarkable.

Israeli Technology Company BYND Cannasoft Enterprises Files US Provisional Patent Application and Full Scale PCT Application for Its EZ-G Device

Retrieved on: 
Monday, July 31, 2023
Intellectual property, CSE, United Nations, Smartphone, Policy, Vibration, Contract management, Intelligence, BYND, Temperature, IP, BCAN, Patent, Collection, United, Machine learning, Pleasure, World Intellectual Property Organization, Artificial intelligence, Human, WIPO, Growth, Female, 3D printing

The patent application listed as Publication Nu m ber WO/2023/13195 was published on the World Intellectual Property Organization’s global database for intellectual property on July 13, 2023.

Key Points: 
  • The patent application listed as Publication Nu m ber WO/2023/13195 was published on the World Intellectual Property Organization’s global database for intellectual property on July 13, 2023.
  • The WIPO application specifically relates to adult toys utilizing one or more sensors for controllable operation and liquid administering mechanism.
  • According to its website, the World Intellectual Property Organization is the global forum for intellectual property (IP) services, policy, information and cooperation.
  • BYND Cannasoft, recognizing the potential in the sextech market, intends to capitalize on this growth.

BYND Cannasoft Provides EZ-G Device Milestones for the Second Half of 2023

Retrieved on: 
Tuesday, July 25, 2023
CSE, Software, BYND, Negotiation, Temperature, Fourth, BCAN, Machine learning, CBD, AI, Heart rate, Health, Sales, 3D printing

ASHKELON, Israel and VANCOUVER, British Columbia, July 25, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") today announced several milestones for the second half of 2023 on the development of its groundbreaking EZ-G Device.

Key Points: 
  • ASHKELON, Israel and VANCOUVER, British Columbia, July 25, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") today announced several milestones for the second half of 2023 on the development of its groundbreaking EZ-G Device.
  • Moreover, the company is actively negotiating with synergistic businesses, particularly those in the CBD oils sector, for a transformative transaction.
  • BYND Cannasoft is pleased to provide the following key milestones in the development of the EZ-G Device:
    Finishing the Prototype of the EZ-G Device in 60 Days: BYND Cannasoft plans to reiterate its commitment to innovation by accomplishing the development of the EZ-G Device's initial prototype within a 60-day timeline.
  • The Company’s team of experts intends to create a prototype that showcases the technology's potential to disrupt the market.